TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23378398

Group type: EXPERIMENTAL
Intervention: Glutamine/amino acid solution
Number of subjects: 106

Group type: COMPARATOR
Intervention: Mother's milk or preterm formula
Number of subjects: 106
Study: 19733508

Group type: EXPERIMENTAL
Intervention: Frenular manual compression with a sponge (Group A)
Number of subjects: 7510

Group type: COMPARATOR
Intervention: Ophthalmologic thermal cautery (Group B)
Number of subjects: 7510
Study: 18528399

Group type: EXPERIMENTAL
Intervention: Sildenafil (n=48)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (n=47)
Number of subjects: 95
Study: 15939246

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate and hydrofluoroalkane (BDP-HFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate and chlorofluorocarbon (BDP-CFC)
Number of subjects: 0
Study: 14719181

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) concentrate (1500 U/day)
Number of subjects: 29
Study: 12544740

Group type: EXPERIMENTAL
Intervention: 5 microg/kg rFVIIa
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 15

Group type: COMPARATOR
Intervention: 10 mL/kg fresh frozen plasma
Number of subjects: 15
Study: 9792579

Group type: EXPERIMENTAL
Intervention: Budesonide forte (1,200 mg/d) for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7707113

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and chemotherapy (vindesine 3 mg/m2 on days 1, 8, 29, and 36; cisplatin 100 mg/m2 on days 1 and 29; mitomycin 8 mg/m2 on days 1 and 29; radiotherapy for 3 weeks with 2 Gy given 13 times)
Number of subjects: 65
Study: 2540136

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Number of subjects: 528
Study: 267373

Group type: EXPERIMENTAL
Intervention: Local application of phenytoin
Number of subjects: 0
Study: 30810254

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg/d for 24 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 27703067

Group type: EXPERIMENTAL
Intervention: Fibrin gel
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 8% Papain gel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Carbopol gel (control)
Number of subjects: 55
Study: 25380051

Group type: EXPERIMENTAL
Intervention: Amphilimus-eluting stent (AES)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cobalt chromium everolimus-eluting stent (EES)
Number of subjects: 112
Study: 24314186

Group type: EXPERIMENTAL
Intervention: Propranolol (2‐3 mg/kg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisolone (1‐4 mg/kg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol with Prednisolone
Number of subjects: 30
Study: 21677329

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19555621

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide administered as a 2-minute bolus (BG)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 10 mg metoclopramide administered as a slow infusion for 15 minutes (IG)
Number of subjects: 68
Study: 16936160

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 1079
Study: 15304173

Group type: EXPERIMENTAL
Intervention: Complete distal aortic occlusion (</=60 min, with heparin and protamine reversal)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bilateral hypogastric artery occlusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: No regional blood flow occlusion
Number of subjects: 56
Study: 11404062

Group type: EXPERIMENTAL
Intervention: Induced sputum by hypertonic saline
Number of subjects: 99

Group type: COMPARATOR
Intervention: Spontaneous sputum (control)
Number of subjects: 99
Study: 9007917

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo toothbrush
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush after switching to placebo
Number of subjects: 50
Study: 8117627

Group type: EXPERIMENTAL
Intervention: Back of artery technique (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Front of artery technique (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Half and half technique (group 3)
Number of subjects: 60
Study: 3653591

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31994476

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD), 600 mg, orally administered
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 15
Study: 31301615

Group type: EXPERIMENTAL
Intervention: bupropion XL 150 mg, 300 mg, 300 mg (once-daily)
Number of subjects: 538

Group type: COMPARATOR
Intervention: escitalopram 10 mg, 10 mg, 10-20 mg (once-daily)
Number of subjects: 538
Study: 29037805

Group type: EXPERIMENTAL
Intervention: Olaparib capsules (400 mg PO b.i.d.)
Number of subjects: 398
Study: 26598077

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 74
Study: 23736824

Group type: EXPERIMENTAL
Intervention: Single‐injection ipsilateral interscalene brachial plexus block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60
Study: 21442813

Group type: EXPERIMENTAL
Intervention: Hour-prescription of points (acupoints of Spleen Meridian selected from 10:04 a.m. to 12:04 a.m.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture (acupoints not selected at 10:04 a.m. to 12:04 a.m.)
Number of subjects: 60
Study: 19295318

Group type: EXPERIMENTAL
Intervention: CNI-free Group (Mycophenolate mofetil [MMF] and sirolimus)
Number of subjects: 63

Group type: COMPARATOR
Intervention: CNI-reduction Group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CNI-free Group
Number of subjects: 63
Study: 17870419

Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chiropractic manual therapy only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Manual therapy followed by exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 15318306

Group type: COMPARATOR
Intervention: Radionuclide methods (99mTc‐diethyl‐IDA injection, 360 MBq)
Number of subjects: 20
Study: 11403533

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of proton pump inhibitors twice daily with H2-receptor antagonist at bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study: 9926165

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (120 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8041415

Group type: EXPERIMENTAL
Intervention: Protracted infusion of fluorouracil during pelvic irradiation
Number of subjects: 660

Group type: COMPARATOR
Intervention: Semustine plus fluorouracil
Number of subjects: 660

Group type: COMPARATOR
Intervention: Higher dose of systemic fluorouracil alone
Number of subjects: 660
Study: 3052971

Group type: EXPERIMENTAL
Intervention: Graduated progressive training (aerobic conditioning and strength exercises) performed twice weekly for 8 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Graduated progressive training
Number of subjects: 18
Study: 31842050

Group type: COMPARATOR
Intervention: SBESS assessment at rest
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SBESS assessment after exertion
Number of subjects: 80

Group type: COMPARATOR
Intervention: SBESS assessment
Number of subjects: 80
Study: 29630516

Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BBAT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional exercises (TEs)
Number of subjects: 20
Study: 29116028

Group type: EXPERIMENTAL
Intervention: PRENACEL (mobile-phone based SMS service)
Number of subjects: 1210
Study: 26099553

Group type: COMPARATOR
Intervention: Low-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (2400 mg/day) for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (4000 mg/day for week 1-2, and 5600 mg/day for week 3-8) for 8 weeks
Number of subjects: 120
Study: 23560469

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study: 21437987

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study: 19166041

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI acquisition techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI interpretation
Number of subjects: 0
Study: 16254130

Group type: EXPERIMENTAL
Intervention: High-temperature whole body hyperthermia (WBH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physical exercise (control group)
Number of subjects: 25
Study: 15062145

Group type: EXPERIMENTAL
Intervention: HDR (high-dose rate) intracavitary brachytherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: MDR (medium-dose rate) intracavitary brachytherapy
Number of subjects: 101
Study: 10920215

Group type: EXPERIMENTAL
Intervention: Continuous oral calcitriol (0.5 microg/day) combined with nasal salmon calcitonin (200 U/day) for the first 3 months (group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous pamidronate (0.5 mg/kg body weight) every third month (group B)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both treatment groups (calcitriol with calcitonin and pamidronate)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 26
Study: 8927947

Group type: EXPERIMENTAL
Intervention: MCT oil
Number of subjects: 6

Group type: COMPARATOR
Intervention: Butter (LCTs)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pancreatic extracts with MCTs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pancreatic extracts with LCTs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MCTs and LCTs together with pancreatic extracts
Number of subjects: 6
Study: 1342819

Group type: COMPARATOR
Intervention: RHSZ 2/7 (Streptomycin, Rifampicin, Hydrazide, Pyrazinamide)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RHZE 2/7 (Ethambutol, Rifampicin, Hydrazide, Pyrazinamide)
Number of subjects: 120
Study: 3877287

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (all other drugs)
Number of subjects: 52
Study: 31786864

Group type: EXPERIMENTAL
Intervention: RFA combined with TACE and entecavir
Number of subjects: 80

Group type: COMPARATOR
Intervention: RFA combined with TACE
Number of subjects: 80
Study: 30532155

Group type: EXPERIMENTAL
Intervention: CETA intervention
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group (standby group without intervention)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Narrative Community‐Based Group Therapy
Number of subjects: 521
Study: 28007205

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 1200
Study: 24528892

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance pathway
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 60
Study: 22113932

Group type: EXPERIMENTAL
Intervention: Non-Luer safety connector system (BD UniVia-6 Safety Connector system)
Number of subjects: 49
Study: 20709517

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100mcg BD) and montelukast (10mg QD)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fluticasone propionate (100mcg BD)
Number of subjects: 103
Study: 17401467

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Naftopidil
Number of subjects: 45
Study: 15571828

Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) during the organization phase for pPCI (Group 1, n=28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) immediately before pPCI (Group 2, n=27)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: abciximab during the organization phase for pPCI (Group 1)
Number of subjects: 55
Study: 12536496

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 9141576

Group type: EXPERIMENTAL
Intervention: Birth centre care
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1860
Study: 7962520

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3034372

Group type: EXPERIMENTAL
Intervention: 1, 3, or 10 micrograms bradykinin after enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1, 3, or 10 micrograms bradykinin after captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1, 3, or 10 micrograms bradykinin after placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 28967075

Group type: EXPERIMENTAL
Intervention: Subretinal aspiration technique (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inverted ILM flap technique (Group B)
Number of subjects: 40
Study: 27353271

Group type: EXPERIMENTAL
Intervention: Velpatasvir (150 mg)
Number of subjects: 70
Study: 25090617

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25.0 mg/day)
Number of subjects: 4695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4695
Study: 23549315

Group type: EXPERIMENTAL
Intervention: Coracoid block (CB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lateral sagittal infraclavicular block (LSIB)
Number of subjects: 100
Study: 20368235

Group type: EXPERIMENTAL
Intervention: prompt revascularization
Number of subjects: 2368

Group type: COMPARATOR
Intervention: intensive medical therapy alone
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: insulin sensitization therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: insulin provision therapy
Number of subjects: 2368
Study: 18782903

Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5.0 mg terbutaline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16634959

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 32
Study: 12928602

Group type: EXPERIMENTAL
Intervention: Vivostat patient-derived fibrin sealant
Number of subjects: 69

Group type: COMPARATOR
Intervention: Surgicel (control)
Number of subjects: 69
Study: 10719944

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 800 microg (three consecutive doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous fentanyl 15 microg/kg
Number of subjects: 12
Study: 9358621

Group type: EXPERIMENTAL
Intervention: HPA-1a allele
Number of subjects: 132

Group type: COMPARATOR
Intervention: HPA-1b allele
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: HPA-2b allele
Number of subjects: 132
Study: 1306814

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2071
Study: 6428843

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 28
Study: 30408272

Group type: EXPERIMENTAL
Intervention: Lip trill therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Straw phonation therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Water-resistance therapy (WRT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham treatment (Control group)
Number of subjects: 35
Study: 30607113

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study: 26744360

Group type: EXPERIMENTAL
Intervention: Grade 1 (very mildly thick) fluid
Number of subjects: 151

Group type: COMPARATOR
Intervention: Grade 2 (mildly thick) fluid
Number of subjects: 151
Study: 25813205

Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (IV) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 and days 15 and 18
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 0
Study: 23045618

Group type: EXPERIMENTAL
Intervention: Multiple-dose DAS181
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 19744223

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 131
Study: 18577791

Group type: EXPERIMENTAL
Intervention: Iron therapy for 12 weeks
Number of subjects: 22
Study: 16172952

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rituximab (MCP+R)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy (MCP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mantle cell lymphoma treatment
Number of subjects: 42
Study: 12394787

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10432137

Group type: EXPERIMENTAL
Intervention: 0.5 mg of PGE2 (Prepidil) administered intracervically at 39 weeks' gestation, repeated weekly for up to three doses.
Number of subjects: 294

Group type: COMPARATOR
Intervention: Expectant treatment (control group).
Number of subjects: 294
Study: 7548458

Group type: EXPERIMENTAL
Intervention: Sons of fathers diagnosed with psychoactive substance dependence (n = 28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Matched sons of nonaffected fathers (n = 26)
Number of subjects: 54
Study: 2111220

Group type: EXPERIMENTAL
Intervention: Glucose-electrolyte solution labeled with stable isotope H2O18
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 0
Study: 6134331

Group type: EXPERIMENTAL
Intervention: Calsyn 100
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Visken
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Grisefuline + Penthonium
Number of subjects: 95
Study: 31402509

Group type: EXPERIMENTAL
Intervention: Nitrogen bisphosphonates (nBP; alendronate or risedronate)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 598

Group type: COMPARATOR
Intervention: Rapid bone loss
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Nitrogen bisphosphonates (nBP)
Number of subjects: 598
Study: 29685019

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCCAs) intravenously, 5.64mL·Kg‐1·h‐1 (4KJ·Kg‐1·h‐1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCCAs) intravenously
Number of subjects: 56
Study: 25288325

Group type: EXPERIMENTAL
Intervention: 4 months' exercise program
Number of subjects: 50
Study: 24495855

Group type: EXPERIMENTAL
Intervention: Open-source random forest
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Open-source tariff method
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: InterVA-4
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: King-Lu method
Number of subjects: 24000

Group type: COMPARATOR
Intervention: Physician-coded verbal autopsy (PCVA)
Number of subjects: 24000
Study: 22101227

Group type: EXPERIMENTAL
Intervention: Methylene blue 200mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylene blue 400mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Methylene blue 100mg IV
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylene blue (200mg and 400mg)
Number of subjects: 22
Study: 20678233

Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioural weight loss intervention focusing on physical activity, diet, and behavioural therapy (18 months duration, with a 6-month intensive phase and a 12-month maintenance phase).
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 300
Study: 17656445

Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min for 60 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study: 16783811

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose 637 mg/day, mean treatment duration 80 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Olanzapine (mean dose 16 mg/day, mean treatment duration 78 days)
Number of subjects: 40
Study: 15283485

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS) with appropriate postoperative care
Number of subjects: 200
Study: 10783609

Group type: EXPERIMENTAL
Intervention: Individual outcome-oriented cardiologic rehabilitation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8627110

Group type: EXPERIMENTAL
Intervention: Mixed antileprosy vaccine containing killed Mycobacterium leprae of human origin plus M. bovis BCG
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: M. bovis BCG
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multidrug therapy (MDT) only
Number of subjects: 50
Study: 1317909

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF)
Number of subjects: 7

Group type: COMPARATOR
Intervention: D‐glucose (placebo)
Number of subjects: 7